Increased time spent on discussing testing for colorectal cancer (CRC) was associated with patient satisfaction in older adults. Adults aged 76 to 85 years were more likely to continue testing for ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing ...

The SimpleScreen CRC test expands Abbott's diagnostic range, which includes Cologuard Plus.

Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential ...

Multigene panel testing should be considered for all patients with colorectal cancer (CRC) who are diagnosed younger than age 50 years, new findings suggest. Among 450 patients with early-onset CRC, ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer ...

SimpleScreen CRC is a blood-based screening test designed to detect colorectal cancer and precancerous lesions. The first-generation version received FDA approval in July 2026 and was commercially ...

Please provide your email address to receive an email when new articles are posted on . Increased use of fecal immunochemical testing correlated with more colorectal cancer screenings and early-stage ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...